Predictive Analytics for the Global Cannabis Industry

© 2019 CB2 Insights
FORWARD-LOOKING STATEMENT

Certain information included in this document contains forward-looking statements concerning CB2 Insights (“the Company”). These include, among others, statements with respect to the company’s goals, objectives and the strategies to achieve these. The words “may”, “will”, “could”, “should”, “suspect”, “outlook” “anticipate”, “forecast”, “objective”, and words similar are intended to identify forward-looking statements.

By their nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that forecasts, projections and other forward-looking statements will not be achieved. Certain assumptions are applied and actual results may differ materially. The Company cautions readers not to place undue reliance on these statements, as a number of important factors, many of which are beyond the Company’s control, could cause actual results to differ materially.

Not-market-specific factors include, but are not limited to risks relating to general business, economic, competitive, political, regulatory and social uncertainties.

The foregoing list of factors that may affect future results is not exhaustive. When reviewing the Company’s forward-looking statements, readers should carefully consider the foregoing factors and other uncertainties and potential events.

This document contains future-oriented financial information and financial outlook information (collectively, “FOFI”) about the Company’s prospective results of operations, sales, revenues, funds flow, and components thereof, all of which are subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraphs. FOFI contained in this document was made as of the date of this document and was provided for the purpose of providing further information about the Company’s future business operations.

The Company disclaims any intention or obligation to update or revise any forward-looking statements or FOFI contained in document, whether as a result of new information, future events or otherwise, unless required pursuant to applicable law. Readers are cautioned that the forward-looking statements or FOFI contained in this document should not be used for purposes other than for which it is disclosed herein.
Big Pharma see $10s of billions in revenue lost to substitution effects.

Governments see opportunities for significant health care cost savings.

Reduction in Traditional Pharma Prescriptions for Medicaid Enrollees in States with Legal Cannabis Programs

<table>
<thead>
<tr>
<th>Condition</th>
<th>Reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychosis</td>
<td>12%</td>
</tr>
<tr>
<td>Seizures</td>
<td>12%</td>
</tr>
<tr>
<td>Depression</td>
<td>13%</td>
</tr>
<tr>
<td>Nausea</td>
<td>17%</td>
</tr>
<tr>
<td>Opioids</td>
<td>11%</td>
</tr>
</tbody>
</table>

Estimated Reduction of Opioid Spend in US

$1.6 Billion  
Source: CDC & JCMP

Estimated Reduction of Anti-Depressant Spend in US

$3.8 Billion  
Source: CDC & Consumer Reports

Source: Bradford & Bradford, Health Affairs, April 2017
"We know there's a lot of anecdotal evidence coming from patients who use medical cannabis to help manage symptoms of their arthritis, but of course we have to put some sort of scientific beef behind that."
- Jason McDougall; Pharmacology and Anesthesia Professor, Dalhousie University

WANTED: CLINICAL CANNABIS RESEARCH

Opportunities for new outlook on cannabis research:

• New legal frameworks in the US has grown to 33 states and Washington DC (represents more than 85% of the population)
• New FDA-driven framework for Real-World Evidence allowing for larger pool of data accepted in lieu of standard clinical trial data
• Greater data collection methodology allowing for tracking of efficacy from initial integration of treatment

Clinically-driven cannabis data & research will play major role in advancing industry over the next 18-24 months.
FRAGMENTED CLINIC GROUPS WITH NO STANDARD DATA PROTOCOLS

- >500 clinics in the United States that specialise in cannabis evaluations and 80% are independent groups (less than 5 clinics within group).
- Approximately 3.5M medical cannabis patients in 2018, representing US$700M+ in annual revenue.
CB2 INSIGHTS STRATEGY: BUILD A DATA ASSET WHILE CONSOLIDATING CLINICS

<table>
<thead>
<tr>
<th>CANNA CARE DOCS</th>
<th>Revenue</th>
<th>EBITDA (adjusted)</th>
<th>Patient Count</th>
<th>Retention Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017</td>
<td>$9,086,791</td>
<td>$831,704</td>
<td>36,608</td>
<td>67%</td>
</tr>
<tr>
<td><strong>CB2 Insights acquired Canna Care Docs in December 2017</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>$10,850,670</td>
<td>$1,911,645</td>
<td>44,114</td>
<td>82%</td>
</tr>
<tr>
<td>Growth Rate</td>
<td>+19.4%</td>
<td>+129.8%</td>
<td>+20.5%</td>
<td>+22.4%</td>
</tr>
</tbody>
</table>

Clinic acquisitions to be purchased at <1X revenue, and for 80% stock & 20% cash.
CB2 BUILDS 360° VIEW OF PATIENTS WITH ADDITIONAL TOOLS

Clinical Operations

Proprietary Technology

Data Insights
ATTENTION: INDUSTRY

“Within healthcare, several conditions and certain patient profiles rely heavily on CBD-only products of which the proposed Farm Bill will work to dramatically improve access to patients – not only in the US but globally,” - Prad Sekar, CEO of CB2 Insights

In a recent study conducted by CB2 Insights, researchers found that over 34 percent of patients seeking medical cannabis were aiming to alleviate mood-related disorders like anxiety, depression, PTSD, and others.

As the industry continues to evolve, big data is ever more critical in the process to best understand every step of the journey.

That said, today’s medical cannabis data lacks standardization. “If cannabis wants to play in the same sandbox as other medications, it really needs to be treated the same way,” - Prad Sekar, CEO of CB2 Insights

[CB2’s] report’s findings couldn’t come at a better time. Cannabis could mitigate the human costs of treating mood disorders in the US.
CLINIC ROLL UP STRATEGY TO FUEL IMMEDIATE GROWTH

Revenue Forecast

2019 2020 2021 2022

$0 $20,000,000 $40,000,000 $60,000,000 $80,000,000 $100,000,000 $120,000,000 $140,000,000

Clinical Operations
Data monetization provides substantial accelerated growth.
# Financial Forecast

Clinical operations remain strong but investment in data business creates substantial inflection point.

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinic Revenue</td>
<td>$20,169,048</td>
<td>$33,952,780</td>
<td>$48,035,572</td>
<td>$62,462,283</td>
</tr>
<tr>
<td>EBITDA from Clinical Operations</td>
<td>$5,042,262</td>
<td>$8,488,195</td>
<td>$14,410,672</td>
<td>$21,861,799</td>
</tr>
<tr>
<td>Margin from Clinical Operations</td>
<td>25%</td>
<td>25%</td>
<td>30%</td>
<td>35%</td>
</tr>
<tr>
<td>Reinvestment in Data Business</td>
<td>$6,434,574</td>
<td>$4,873,593</td>
<td>$4,356,236</td>
<td>$3,763,371</td>
</tr>
<tr>
<td>Revenue from Tech &amp; Data Business</td>
<td>$515,497</td>
<td>$3,735,980</td>
<td>$30,576,685</td>
<td>$57,207,896</td>
</tr>
<tr>
<td>Consolidated EBITDA</td>
<td>($1,392,312)</td>
<td>$7,350,582</td>
<td>$40,631,121</td>
<td>$75,306,324</td>
</tr>
<tr>
<td>Consolidated Margin</td>
<td>-7%</td>
<td>20%</td>
<td>52%</td>
<td>63%</td>
</tr>
</tbody>
</table>
## CURRENT CAP STRUCTURE

<table>
<thead>
<tr>
<th>Type of Shares</th>
<th>Shares (millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Common Shares Outstanding*</td>
<td>75.8</td>
</tr>
<tr>
<td>Options</td>
<td>6.1</td>
</tr>
<tr>
<td>Warrants</td>
<td>16.5</td>
</tr>
<tr>
<td><strong>Fully Diluted Shares</strong></td>
<td><strong>98.4</strong></td>
</tr>
</tbody>
</table>

The company recently completed an over-subscribed C$5.74 million raise at $0.50/unit with **Merida Capital Partners**, a private equity fund based out of New York, whose investment focus is **cannabis-related businesses**. Merida accounted for $3.68 million of what was originally a C$5.0 million raise.

Notes:
* Founders hold ~20% of Outstanding Common Shares
March 14, 2019

**AI Pioneer Dr. Randy Goebel joins CB2 Insights to Advance its Predictive Insights Platform**

- Professor in the Department of Computing Science at the University of Alberta (UofA)
- On advisory board for German Research Centre for AI, and
- Involved with development of the UofA Google DeepMind relationship (group behind AlphaGo)

March 27, 2019

**CB2 Insights Signs Agreement with Premier Health to Integrate Medical Cannabis Clinical Decision Support Tool**

- Leading Electronic Medical Records (EMR) platform to integrate CB2’s Clinical Decision Support Tool into platform
- Leveraging CB2’s extensive data assets to assist nearly 5,000 physicians to evaluate patients on the integration of cannabis into various treatment plans

March 20, 2019

**CB2 Insights Signs Agreement to Acquire Medical Cannabis Clinic Group in Colorado and Arizona**

Details of acquisition:
- Prior year revenue: CA$1.0 million
- Acquisition value: US$375,000
- Cash consideration: US$150,000
- Stock consideration: 450,000 shares @ US$0.50/share

April 4, 2019

**CB2 Insights Acquires Multi-Location Medical Cannabis Clinic Group, Relaxed Clarity**

Details of acquisition:
- Prior year revenue: CA$1.4 million
- Acquisition value: US$450,000
- Cash consideration: US$200,000
- Stock consideration: 500,000 shares @ US$0.50/share
SUMMARY

- Opportunity: Cannabis disruption of traditional pharma in the $10’s of billions
- Highly fragmented medical cannabis clinic market
- CB2 Insights uniquely positioned as consolidator & provider of cannabis data
- Oversubscribed raise, led by a private equity fund that is targeting the fundamental growth drivers underpinning the rapid development of the cannabis industry
- Attractive valuation
Thank You

Gareth Tingling
Investor Relations
investors@cb2insights.com
(647) 362-8286